HEPATOLOGY / STATE OF THE ART PAPER
 
KEYWORDS
TOPICS
ABSTRACT
The precise assessment of liver fibrosis degree is imperative for monitoring and managing chronic liver diseases. Traditionally, liver biopsy and quantitative blood biomarkers have been the mainstays for fibrosis assessment, albeit each with its inherent limitations. However, the emergence of elastography presents a promising non-invasive alternative, potentially supplanting or complementing traditional biomarkers. In contrast to conventional biomarkers, elastography offers several advantages. Firstly, it is non-invasive, sidestepping the risks and discomfort associated with liver biopsy. Secondly, this technique provides real-time and intuitive fibrosis assessments, characterized by user-friendly operation and high reproducibility. Thirdly, elastography excels in diagnosing moderate to severe fibrosis, is vital for determining treatment strategies and monitoring disease progression. Notably, MRE stands out as the most accurate non-invasive method for fibrosis assessment, especially suitable for advanced fibrotic stages. This article provides an overview of the advancements in elastography as a viable quantitative biomarker for chronic liver disease fibrosis burden.
 
REFERENCES (40)
1.
Kamada Y, Nakamura T, Isobe S, et al. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum. J Gastroenterol 2023; 58: 79-97.
 
2.
Barnard Giustini A, Ioannou GN, Sirlin C, et al. Review article: available modalities for screening and imaging diagnosis of hepatocellular carcinoma-Current gaps and challenges. Aliment Pharmacol Ther 2023; 57: 1056-65.
 
3.
Pons M, Augustin S, Scheiner B, et al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease. Am J Gastroenterol 2021; 116: 723-32.
 
4.
Corpechot C, Carrat F, Gaouar F, et al. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. J Hepatol 2022; 77: 1545-53.
 
5.
Hinkson A, Lally H, Gibson H, et al. Meta-analysis: enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases. Aliment Pharmacol Ther 2023; 57: 750-62.
 
6.
Mózes FE, Lee JA, Vali Y, et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol 2023; 8: 704-13.
 
7.
Papatheodoridi M, Pallini G, Aithal G, et al. Health-related quality of life in patients with nonalcoholic fatty liver disease: a prospective multi-center UK study. Clin Gastroenterol Hepatol 2023; 21: 3107-14.e3103.
 
8.
Kakegawa T, Sugimoto K, Kuroda H, et al. Diagnostic accuracy of two-dimensional shear wave elastography for liver fibrosis: a multicenter prospective study. Clin Gastroenterol Hepatol 2022; 20: e1478-82.
 
9.
Graupera I, Thiele M, Serra-Burriel M, et al. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin Gastroenterol Hepatol 2022; 20: 2567-76.e2566.
 
10.
Abu-Freha N, Mathew Jacob B, Elhoashla A, et al. Chronic hepatitis C: diagnosis and treatment made easy. Eur J Gen Pract 2022; 28: 102-8.
 
11.
Im WH, Song JS, Jang W. Noninvasive staging of liver fibrosis: review of current quantitative CT and MRI-based techniques. Abdom Radiol 2022; 47: 3051-67.
 
12.
Long MT, Noureddin M, Lim JK. AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review. Gastroenterology 2022; 163: 764-74.e761.
 
13.
Lim DH, Kim M, Jun DW, et al. Diagnostic performance of serum asialo (1)-acid glycoprotein levels to predict liver cirrhosis. Gut Liver 2021; 15: 109-16.
 
14.
Semmler G, Yang Z, Fritz L, et al. Dynamics in liver stiffness measurements predict outcomes in advanced chronic liver disease. Gastroenterology 2023; 165: 1041-52.
 
15.
Chen H, Shen Y, Wu SD, et al. Diagnostic role of transient elastography in patients with autoimmune liver diseases: a systematic review and meta-analysis. World J Gastroenterol 2023; 29: 5503-25.
 
16.
Rinella ME, Dufour JF, Anstee QM, et al. Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study. J Hepatol 2022; 76: 536-48.
 
17.
Herrera-Quiñones G, Da Fieno AM, Compta Y, et al. Considerations for optimizing Wilson’s disease patients’ long-term follow-up. Gastroenterol Hepatol 2022; 45: 146-54.
 
18.
Nogami A, Iwaki M, Kobayashi T, et al. Real-world assessment of SmartExam, a novel FibroScan computational method: a retrospective single-center cohort study. J Gastroenterol Hepatol 2023; 38: 321-9.
 
19.
Segna D, Mendoza YP, Lange NF, et al. Non-invasive tools for compensated advanced chronic liver disease and portal hypertension after Baveno VII – an update. Dig Liver Dis 2023; 55: 326-35.
 
20.
Vilar-Gomez E, Vuppalanchi R, Gawrieh S, et al. CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population. Hepatology 2023; 77: 1241-52.
 
21.
Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: past, present and future. J Hepatol 2022; 76: 1362-78.
 
22.
Pepin KM, Welle CL, Guglielmo FF, et al. Magnetic resonance elastography of the liver: everything you need to know to get started. Abdom Radiol (NY) 2022; 47: 94-114.
 
23.
Sanyal AJ, Foucquier J, Younossi ZM, et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. J Hepatol 2023; 78: 247-59.
 
24.
Man S, Deng Y, Ma Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China. Gastroenterology 2023; 165: 1025-40.
 
25.
Tao ZZ, Wang YL, Sun YH, et al. Comparison of different Young’s modulus determination by two-dimensional shear wave elastography in predicting liver fibrosis in patients with chronic hepatitis B. J Prac Hepatol 2023; 26: 328-31.
 
26.
Osman AM, El Shimy A, Abd El Aziz MM. 2D shear wave elastography (SWE) performance versus vibration-controlled transient elastography (VCTE/fibroscan) in the assessment of liver stiffness in chronic hepatitis. Insights Imaging 2020; 11: 38.
 
27.
Guo H, Liao M, Jin J, et al. How intrahepatic cholestasis affects liver stiffness in patients with chronic hepatitis B: a study of 1197 patients with liver biopsy. Eur Radiol 2020; 30: 1096-104.
 
28.
Ekin N, Ucmak F, Ebik B, et al. GPR, King’s Score and S-Index are superior to other non-invasive fibrosis markers in predicting the liver fibrosis in chronic hepatitis B patients. Acta Gastroenterol Belg 2022; 85: 62-8.
 
29.
Kavak S, Kaya S, Senol A, et al. Evaluation of liver fibrosis in chronic hepatitis B patients with 2D shear wave elastography with propagation map guidance: a single-centre study. BMC Med Imaging 2022; 22: 50.
 
30.
Fan R, Li G, Yu N, et al. aMAP score and its combination with liver stiffness measurement accurately assess liver fibrosis in chronic hepatitis B patients. Clin Gastroenterol Hepatol 2023; 21: 3070-9.e3013.
 
31.
Yin M, Ehman RL. MR elastography: practical questions, from the AJR special series on imaging of fibrosis. AJR Am J Roentgenol 2024; 222: e2329437.
 
32.
Wang Y, Zhou J, Lin H, et al. Viscoelastic parameters derived from multifrequency MR elastography for depicting hepatic fibrosis and inflammation in chronic viral hepatitis. Insights Imaging 2024; 15: 91.
 
33.
Kalaiyarasi K, Sanchalika A, Hsien Min L, et al. Transient elastography is the best-performing non-invasive test of liver fibrosis in obese asian patients with non-alcoholic fatty liver disease: a pilot, cross-sectional study. Medicina (Kaunas) 2024; 60: 169.
 
34.
Moura Cunha G, Fan B, Navin PJ, et al. Interpretation, reporting, and clinical applications of liver MR elastography. Radiology 2024; 310: e231220.
 
35.
Zerunian M, Masci B, Caruso D, et al. Liver magnetic resonance elastography: focus on methodology, technique, and feasibility. Diagnostics (Basel) 2024; 14: 379.
 
36.
Kobayashi T, Iwaki M, Nogami A, et al. Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography. J Gastroenterol 2024; 59: 56-65.
 
37.
Feuille C, Kari S, Patel R, et al. Utility and impact of magnetic resonance elastography in the clinical course and management of chronic liver disease. Sci Rep 2024; 14: 1765.
 
38.
Han X, Yang D, Xu H, et al. Superiority of spleen stiffness on two-dimensional magnetic resonance elastography over liver stiffness and serum tests in assessing portal hypertension in chronic liver disease. Quant Imaging Med Surg 2024; 14: 1429-40.
 
39.
Duarte-Rojo A, Taouli B, Leung DH, et al. Imaging-based non-invasive liver disease assessment for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD Practice Guideline. Hepatology 2024. doi: 10.1097/HEP.0000000000000852.
 
40.
Demirtaş D, Ünal E, İdilman İS, et al. Magnetic resonance elastography in evaluation of liver fibrosis in children with chronic liver disease. Insights Imaging 2023; 14: 39.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top